Trials / Recruiting
RecruitingNCT06073873
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- —
Summary
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | According to local product label |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2023-10-10
- Last updated
- 2024-08-22
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06073873. Inclusion in this directory is not an endorsement.